J33.0 Insurance Policy Changes

ICD-10 J33.0 is officially defined as "Polyp of nasal cavity." code J33.0 is referenced in 7 tracked payer policy changes from UnitedHealthcare, Independence Blue Cross, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code J33.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

UnitedHealthcare · Effective Oct 1, 2026Medium impact
Xolair ® (Omalizumab)
UnitedHealthcare Community Plan of Indiana has revised its Xolair (omalizumab) policy effective October 1, 2026, clarifying that provider-administered subcutaneous injections are covered for chronic urticaria, IgE-mediated food allergy, moderate-to-severe persistent asthma, and nasal polyps, while self-administered injections fall under pharmacy benefits. The policy also explicitly identifies conditions where Xolair is NOT covered (seasonal/perennial allergic rhinitis, atopic dermatitis, acute bronchospasm, anaphylaxis). Indiana is now included in coverage (previous policy excluded it).
Independence Blue Cross · Effective Jun 15, 2026Medium impact
MA08.144c, Tezepelumab-ekko (Tezspire®)
Independence Blue Cross Medicare Advantage added chronic rhinosinusitis with nasal polyposis (CRSwNP) as a newly covered indication for tezepelumab-ekko (Tezspire) effective June 15, 2026. This expands the drug's coverage beyond severe asthma to include nasal polyp patients meeting specific clinical criteria. Billing teams must begin accepting claims with new CRSwNP diagnosis codes (J32.0-J32.9 and J33.0-J33.9) when paired with the HCPCS code J2356 for Medicare Advantage members.
Aetna · Identified Sep 29, 2026Medium impact
Omalizumab (CPB 0670, reviewed 2026-08-21)
Aetna Clinical Policy Bulletin 0670 sets the coverage criteria for omalizumab (Xolair) and its biosimilar omalizumab-igec (Omlyclo) under commercial medical plans. Covered indications are asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, IgE-mediated food allergy, refractory immune checkpoint inhibitor-related pruritus, and systemic mastocytosis, each with listed criteria such as diagnosis, pre-treatment IgE level, prior therapy and continued positive clinical response. Precertification is required in applicable plan designs and the Site of Care Utilization Management Policy applies, and Aetna considers all other indications, including allergic rhinitis, atopic dermatitis and eosinophilic esophagitis, experimental, investigational or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Tezepelumab-ekko (Tezspire) (CPB 1003, reviewed 2026-08-06)
Aetna's clinical policy for tezepelumab-ekko (Tezspire) covers it for commercial medical plans when it is medically necessary for severe asthma in members 12 years of age or older, or for chronic rhinosinusitis with nasal polyps (CRSwNP) in members 12 years of age or older, under the listed criteria. Asthma criteria include uncontrolled asthma within the past 12 months and inadequate control despite high dose inhaled corticosteroid plus an additional controller, or prior use of a biologic for asthma within the past 12 months. CRSwNP criteria include bilateral nasal polyposis and chronic sinusitis symptoms despite intranasal corticosteroids, plus prior sinonasal surgery or ineffective systemic corticosteroids within the last 24 months. Members cannot use it concomitantly with any other biologic or targeted synthetic drug for the same indication, and Aetna considers all other indications experimental, investigational, or unproven, including allergic broncho-pulmonary aspergillosis and combined tezepelumab and allergen immunotherapy for allergic rhinitis.
Aetna · Identified Aug 16, 2026Medium impact
Sinus Surgeries (CPB 0937, reviewed 2026-04-10)
Aetna's Clinical Policy Bulletin 0937 treats endoscopic sinus surgery as medically necessary for specific indications, including allergic fungal rhino-sinusitis with CT evidence, antro-choanal polyp, chronic rhino-sinusitis longer than 12 continuous weeks with or without nasal polyps that has failed maximal medical treatment and shows objective CT evidence, recurrent acute rhino-sinusitis meeting listed criteria, sinusitis complications, and mucocele, and as experimental, investigational, or unproven for all other indications. Revision surgery requires at least 12 weeks since the previous surgery, chronic rhino-sinusitis for at least 12 continuous weeks, failure of at least one 5 to 7 day course of antibiotics since the previous surgery, and persistent objective CT evidence of sinus disease. Balloon sinus ostial dilation is medically necessary for uncomplicated sinusitis without nasal polyposis when the Appendix criteria are met and is experimental for listed cases such as nasal polyposis grade 2 or greater, repeat balloon procedures, and Samter's triad, while sphenopalatine artery ligation with posterior nasal nerve ablation is experimental for vasomotor rhinitis.
Aetna · Identified Aug 16, 2026Medium impact
Mepolizumab (Nucala) (CPB 0897, reviewed 2026-08-05)
Aetna considers mepolizumab (Nucala) medically necessary for commercial medical plans when the criteria for an indication are met. The covered indications are severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). Aetna considers all other indications experimental, investigational, or unproven, and the drug may not be used with another biologic or targeted synthetic drug for the same indication.
Aetna · Identified Aug 16, 2026Medium impact
Mometasone Furoate Sinus Implant (Sinuva) (CPB 0935, reviewed 2025-12-23)
Aetna considers the mometasone furoate sinus implant (Sinuva) medically necessary for recurrent nasal polyps in members 18 years of age and older who have had ethmoid sinus surgery, would otherwise be candidates for revision sinus surgery, and have nasal obstruction or congestion symptoms despite use of intranasal steroid irrigations or sprays. Repeat administration is medically necessary for members with ethmoid sinus polyps grade of 1 or higher on any side. All other indications are considered experimental, investigational, or unproven.

Watch J33.0

Get one email when a payer policy names J33.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code J33.0?

There are 7 tracked policy changes affecting code J33.0, including updates from UnitedHealthcare, Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code J33.0?

Payers that have issued tracked updates for code J33.0 include: UnitedHealthcare, Independence Blue Cross, Aetna.

How do I get notified when code J33.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code J33.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code J33.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Xolair ® (Omalizumab)

MA08.144c, Tezepelumab-ekko (Tezspire®)

Omalizumab (CPB 0670, reviewed 2026-08-21)

Tezepelumab-ekko (Tezspire) (CPB 1003, reviewed 2026-08-06)

Sinus Surgeries (CPB 0937, reviewed 2026-04-10)

Mepolizumab (Nucala) (CPB 0897, reviewed 2026-08-05)

Mometasone Furoate Sinus Implant (Sinuva) (CPB 0935, reviewed 2025-12-23)

What insurance policy changes affect code J33.0?

Which payers have updated policy for code J33.0?

How do I get notified when code J33.0 policy changes?

Why do payers change policies for code J33.0?